UPDATE: Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease Unlikely to Increase Risk of Mortality – Letter to Health Care Providers

July 11, 2023 The U.S. Food and Drug Administration (FDA) is informing health care providers about updated information associated with paclitaxel-coated devices used to treat peripheral arterial disease (PAD). Based on the FDA’s review of the totality of the available data and analyses, we have determined that the data does not support an excess mortality…

Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect

Summary Company Announcement Date: July 06, 2023 FDA Publish Date: July 07, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Failure to deliver the recommended dose Company Name: Cipla Brand Name: Brand Name(s) Product Description: Product Description Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Company Announcement FOR IMMEDIATE RELEASE – Mumbai,…

How to Report Problems with E-Cigarettes, Cigarettes, Cigars, or Other Tobacco Products to the FDA

[embedded content] Español How can I report problems with tobacco products? The Safety Reporting Portal (SRP) allows you to tell the U.S. Food and Drug Administration’s Center for Tobacco Products about health, quality, or safety issues with tobacco products, including products containing nicotine from any source. Reports about unexpected tobacco-related health or product problems can…

UPDATE: NuVasive Specialized Orthopedics’ Precice Devices – Letter to Health Care Providers

June 28, 2023 The U.S. Food and Drug Administration (FDA) is providing an update to information and recommendations for the NuVasive Specialized Orthopedics’ (NuVasive) Precice Intra-medullary Limb Lengthening (IMLL) system, which includes Precice Short.  In March 2023, NuVasive received FDA 510(k) clearance for the expanded use of the Precice IMLL system (including Precice Short) for…

FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

Podcast Welcome back to the D.I.S.C.O., FDA’s Drug Information Soundcast in Clinical Oncology, Burst Edition, brought to you by FDA’s Division of Drug Information in partnership with FDA’s Oncology Center of Excellence. Today we’ll provide a quick update on a recent FDA cancer drug approval. On May 19, 2023, the FDA granted accelerated approval to…

How to Properly Store E-Liquids and Prevent Accidental Exposure of E-Liquids to Children

Español As e-cigarettes (also called “vapes”) have become more popular, more children are being accidentally exposed to nicotine-containing e-liquids—which can cause injury and even death. If you’re an adult who vapes, the U.S. Food and Drug Administration wants you to know that it’s important to keep these products away from kids, and to be prepared…

The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg Due to Label Mix-up

Summary Company Announcement Date: June 13, 2023 FDA Publish Date: June 14, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Packaging may contain incorrect product due to labeling mix-up Company Name: The Harvard Drug Group, LLC d/b/a Major Pharmaceutical and Rugby Laboratories Brand Name: Brand Name(s) Major Pharmaceuticals Product Description: Product Description Dronabinol…